Omacetaxine (Synribo)
In clinical trials. May also be known as homoharringtonine (HHT).
General information
Class/mechanism: Semisynthetic form of homoharringtonine (HHT), which is a natural alkaloid that inhibits protein synthesis (such as human induced myeloid leukemia cell differentiation protein MCL1), promotes apoptosis, and is being investigated for its activity in imatinib-resistant chronic myeloid leukemia (CML) patients with the T315I mutation.[1]
Route: IV, SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.
References
- ↑ Quintás-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009 Dec 1;115(23):5382-93. link to original article PubMed